Strain Profile
Save
Limosilactobacillus reuteri DSM 17938
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Limosilactobacillus reuteri DSM 17938 (formerly Lactobacillus reuteri DSM 17938) has been studied in multiple randomized controlled trials and at least one published meta-analysis examining infantile colic, episodes of prolonged, unexplained crying in otherwise healthy babies. These trials, predominantly conducted in breastfed infants, have examined crying time as an outcome measure, though study designs and populations vary. The strain has also been investigated in the context of infant regurgitation and constipation, and in vitro work has explored its oral health properties. Research in older age groups and for adult indications remains more limited. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 400 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 245 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+14 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
578 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
ANIMAL
2026
RCT
2026
IN_VITRO
2026
IN_VITRO
2026
META_ANALYSIS
2026
REVIEW
2026
ANIMAL
2026
RCT
2026
IN_VITRO
2026
REVIEW
2026
REVIEW
2026
RCT
2026
IN_VITRO
2026
OBSERVATIONAL
2026
ANIMAL
2026
META_ANALYSIS
2026
RCT
2026
META_ANALYSIS
2026
ANIMAL
2026
IN_VITRO
Browse all 578 papers →
Lactobacillus reuteri DSM 17938 Improves Intestinal Motility in Mice With Postoperative Ileus by Modulating Gut Microbiota and Macrophage
· Neurogastroenterology & Motility
Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders
· Nutrients
Curd encapsulation of Limosilactobacillus reuteri for efficient and cost-effective production of reuterin from glycerol
· Bioresource Technology Reports
Gluten-Free Steamed Bread Formulated with Rice–Amaranth Flours via Sourdough Fermentation
· Fermentation
Comparative efficacy of probiotic, prebiotic, and synbiotic interventions in children with functional abdominal pain disorders: a systematic review and network meta-analysis
· Frontiers in Nutrition
Efficacy and Safety of Limosilactobacillus reuteri DSM 17938 in Infantile Colic: A Narrative Review From Pathogenesis to Clinical Practice
· Cureus
B33-15 Probiotic Limosilactobacillus Reuteri Attenuates Lung Inflammation in a Murine Model of Treg Deficiency
· American Journal of Respiratory and Critical Care Medicine
Limosilactobacillus reuteri DSM 17938 and Colic Prevention in Infants: A Randomized Controlled Trial
· SSRN Electronic Journal
Limosilactobacillus reuteri metabolites modulate immune pathways and intestinal barrier repair after 5 fluorouracil exposure
· Scientific Reports
Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic‐associated diarrhoea in children
· Journal of Pediatric Gastroenterology and Nutrition
In infants with colic, does the administration of probiotics, compared to placebo or control, reduce crying time and/or improve symptoms?
· Zenodo (CERN European Organization for Nuclear Research)
Probiotic Supplementation to Prevent Diaper Dermatitis in Antibiotic-Treated Neonates: Secondary Analysis of a Randomised Controlled Trial
· Children
In Vitro Evaluation of the Uric Acid Degrading Activity by Limosilactobacillus Reuteri DSM 17938 Under Simulated Gastrointestinal Conditions
· INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND ANALYSIS
Impact of Limosilactobacillus reuteri DSM 17938 on early-life gut microbial diversity
· World Journal of Clinical Pediatrics
Limosilactobacillus reuteri-educated T cells protect against activation of liver inflammation in immunocompromised mice 2229185
· The Journal of Immunology
Efficacy and Safety of Lactobacillus reuteri DSM 17938 in Pediatric Functional Abdominal Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
· Nutrients
Comparison of Lactobacillus reuteri DSM 17938 versus placebo in the management of functional abdominal pain in children aged 4-12 years: A randomized double-blind placebo-controlled trial
· International Journal of Pediatrics and Neonatology
Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis
· World Journal of Gastroenterology
Lactobacillus reuteri DSM 17938 and Its Supernatant Ameliorate Parkinson’s Disease in Association with Modulation of Gut Microbiota and Its Tryptophan Metabolism
· Antioxidants
In Vitro Comparison of Four Listerine Mouthwash Formulations on the Inhibition of Lactobacillus reuteri DSM 17938 and Human Oral Microbiota
· Open Journal of Stomatology
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Efficacy and Safety of Lactobacillus reuteri DSM 17938 in Pediatric Functional Abdominal Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials· Nutrients · 2026
-
[2]
Source →Comparison of Lactobacillus reuteri DSM 17938 versus placebo in the management of functional abdominal pain in children aged 4-12 years: A randomized double-blind placebo-controlled trial· International Journal of Pediatrics and Neonatology · 2026
-
[3]
Source →In infants with colic, does the administration of probiotics, compared to placebo or control, reduce crying time and/or improve symptoms?· Zenodo (CERN European Organization for Nuclear Research) · 2026
-
[4]
Source →Efficacy and Safety of Limosilactobacillus reuteri DSM 17938 in Infantile Colic: A Narrative Review From Pathogenesis to Clinical Practice· Cureus · 2026
-
[5]
PMID 41486369 →Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic‐associated diarrhoea in children· Journal of Pediatric Gastroenterology and Nutrition · 2026
-
[6]
PMID 41883407 →Comparative efficacy of probiotic, prebiotic, and synbiotic interventions in children with functional abdominal pain disorders: a systematic review and network meta-analysis· Frontiers in Nutrition · 2026
-
[7]
PMID 41754204 →Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders· Nutrients · 2026
-
[8]
PMID 41853274 →Limosilactobacillus reuteri alleviates proinflammatory T-cell-mediated liver injury and transcriptomic changes in immunocompromised mice· Frontiers in Immunology · 2026
-
[9]
Source →All data from Limosilactobacillus reuteri promotes melatonin release from human intestinal organoids via 5’ectonucleotidase activity· Figshare · 2026
-
[10]
PMID 41913515 →Probiotic use in French neonatal intensive care units: A nationwide analysis of practice patterns and clinical outcomes· Journal of Pediatric Gastroenterology and Nutrition · 2026